US-CONGRESS BILLS-119hr9661ih: Expedited Access to Biosimilars Act
The Expedited Access to Biosimilars Act (H.R. 9661) proposes to streamline FDA approval for biosimilars, potentially reducing market exclusivity periods for branded biologics and accelerating competition. This could impact pricing, supply chain strategies, and regulatory timelines for all pharmaceutical manufacturers.
Aforeworn detected this change in the Pharmaceutical Manufacturing (FDA/DEA) space on July 16, 2026 and published this briefing so affected operators are forewarned rather than caught off guard. It is rated Medium urgency. Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B) should confirm how it applies to their specific situation before acting. There is a time constraint attached: No immediate deadline; bill is in early stages. Track committee hearings and markups.. Acting after that point can mean penalties, a lapsed licence, or lost eligibility — exactly the kind of surprise Aforeworn exists to prevent. Aforeworn monitors Pharmaceutical Manufacturing (FDA/DEA) continuously and turns every detected change into a plain-English briefing like this one, so you always know first. Forewarned is forearmed.
What changed
The bill introduces expedited approval pathways for biosimilars, which may shorten exclusivity periods and increase competition for biologic drugs.
Who it affects
Branded drug makers, generic/ANDA manufacturers, API & contract manufacturers, compounding outsourcing (503B)
What you must do
Monitor legislative progress; assess potential impact on product portfolios and R&D pipelines; prepare for faster market entry of biosimilars.
Deadline
No immediate deadline; bill is in early stages. Track committee hearings and markups.
Source: https://www.govinfo.gov/app/details/BILLS-119hr9661ih
Never miss a change like this again
Aforeworn watches Pharmaceutical Manufacturing (FDA/DEA) around the clock and alerts you the moment a rule moves — with a plain-English brief on what to do.
Start your free trialRelated changes in Pharmaceutical Manufacturing (FDA/DEA)
- Process for FDA Data Requests To Inform Certain Over-the-Counter Monograph Drug Activities; Procedure
- FDA drafts new ultra-rare disease therapy guidance - European Pharmaceutical Review
- FDA Proposal Would Leave Semaglutide, Tirzepatide, and Liraglutide Off 503B Bulks List - The National Law Review
- IL HB0004: MEDICAID-PHARMACY SERVICES
- Drugs for Human Use; Drug Efficacy Study Implementation: Estrogen-Androgen Fixed-Combination Drug Products; Extension of Effective Date of Final Resolution of Drug Efficacy Study Implementation 7661